Top Markets
#1 DogBull DogBull +105.13%
#2 Siacoin Siacoin +54.09%
#3 ADO Protocol ADO Protocol +46.53%
#4 MarsCoin MarsCoin +44.60%
#5 UnifAI Network UnifAI Network +44.55%
#6 Useless Coin Useless Coin +23.36%
#7 Magma Finance Magma Finance +22.74%
#8 Ontology Gas Ontology Gas +22.45%
#9 Apertum Apertum +14.61%
#10 Filecoin Filecoin +13.89%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Opus Genetics, Inc. Opus Genetics, Inc.

Opus Genetics, Inc.

IRD
Rank in Stocks #16217
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on... Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Share Price
$3.70
Last synced: 2026-07-31
Market Cap
$305.87M
Change (1 day)
-3.53%
Change (1 year)
203.66%
Country
US
Trade Opus Genetics, Inc. (IRD)

Category

Healthcare
P/E ratio for Opus Genetics, Inc. (IRD)
P/E ratio as of 2026 TTM: 0
According to Opus Genetics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Opus Genetics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.